ASAnna M. Sawka

Anna M. Sawka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna M. Sawka has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer

    by Anna M Sawka, Sangeet Ghai, Lorne Rotstein, Jonathan C Irish, Jesse D Pasternak, Eric Monteiro, Janet Chung, Jie Su, Wei Xu, Alex O Esemezie, et al.

    Importance: In managing early-stage cancers, active surveillance (AS) may be preferentially favored by older individuals. In counseling patients, it is important to understand the durability of AS in the context of age.Objective: To evaluate the durability of AS in patients with small, low-risk papillary thyroid cancer (PTC) according to age at the time of choosing AS.Design, Setting, and Participants: This single-center, prospective, long-term follow-up cohort study was conducted at a tertiary care hospital in Toronto, Ontario, Canada. Adult patients with small, localized, low-risk PTC less than 2 cm in maximal diameter were enrolled between May 2016 and February 2021. The clinical outcome data were analyzed up to the time point of May 25, 2025, and final data analysis was performed in June 2025.Exposure: All patients were offered the choice of AS or thyroid surgery.Main Outcomes and Measures: The primary outcome was the overall rate of AS crossover to definitive treatment (treatment completed or recommended by an investigator) and the indications. Cumulative crossover incidence function curves were examined according to age, with death from other causes as the competing risk.Results: A total of 200 patients (155 patients under AS and 45 who had immediate surgery) were followed up for a median (IQR) duration of 71 (59-84) months. Overall mean (SD) age was 52.0 (14.9) years, and 153 patients (76.5%) were female. There were no observed thyroid cancer–related deaths or any distant metastatic disease. The overall crossover rate from AS was 23.9% (37/155; 32 completed treatment, 3 declined surgery for disease progression, and 2 awaiting treatment). Crossover reasons included disease progression (56.8% [21/37]), patient preference (40.5% [15/37]), and ultrasound imaging limitations precluding accurate tumor measurement under active surveillance (tumor border not clearly distinguishable from heterogeneous echotexture of the thyroid parenchyma in a patient with Hashimoto thyroiditis; 2.6% [1/37]). The 5-year age-stratified cumulative overall crossover incidence rates were 41.5% (95% CI, 25.6%-56.8%) in patients younger than 45 years, 20.9% (95% CI, 12.3%-31.1%) in those aged 45 to 64 years, and 5.1% (95% CI, 0.9%-15.2%) in those aged 65 years and older (P < .001).Conclusion and Relevance: This single-center Canadian cohort study found that AS is a durable long-term management strategy for small, low -risk PTC, particularly in older individuals. Older individuals may be less likely to cross over to surgery after choosing AS.


  • Open Access

    Decision Regret Following the Choice of Surgery or Active Surveillance for Small, Low-Risk Papillary Thyroid Cancer: A Prospective Cohort Study

    by Anna M. Sawka, Sangeet Ghai, Lorne Rotstein, Jonathan C. Irish, Jesse D. Pasternak, Eric Monteiro, Janet Chung, Afshan Zahedi, Jie Su, Wei Xu, et al.

    Background: It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. Methods: We performed a prospective observational cohort study of Canadian patients with small (p = 0.730) or adjusted ( p = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3–18.9], p = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS ( p = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. Conclusions: In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.


  • Open Access

    Gender Differences in Fears Related to Low-Risk Papillary Thyroid Cancer and Its Treatment

    by Anna M. Sawka, Sangeet Ghai, Lorne Rotstein, Jonathan C. Irish, Jesse D. Pasternak, Patrick J. Gullane, Eric Monteiro, Afshan Zahedi, Everton Gooden, Antoine Eskander, et al.

    Individuals diagnosed with thyroid cancer are known to experience distressing emotions, including shock, fear, and anxiety.1-3 Concerns expressed by patients with newly diagnosed low-risk papillary thyroid cancer (PTC) relate to the cancer and its associated future outcome uncertainty as well as the potential risks and consequences of its treatment (eg, thyroidectomy).4 It is important to fully understand the fears experienced by individuals newly diagnosed with thyroid cancer to inform supportive care strategies and patient counseling. This understanding may be more fully informed in considering the context of gender.


  • Women and thyroid cancer incidence: overdiagnosis versus biological risk

    by Diana Lam, Louise Davies, Anna M. Sawka

    Purpose of the review: Our aim is to discuss the concepts of sex and gender in the context of thyroid cancer epidemiology. Recent findings: It has been long-established in global epidemiologic data that thyroid cancer incidence rates are higher in women than men. However, what has been less well understood is whether this reflects sex disparities in cancer susceptibility, gender disparities in detection, or a combination. A recent meta-analysis of autopsy data from individuals who were not known to have thyroid cancer in their lifetime demonstrated no difference in the prevalence of thyroid cancer in women and men, suggesting that gender differences may be the reason for gender-based differences in thyroid cancer detection. This finding, and sex differences in auto immunity and other factors that may affect cancer susceptibility are explored. Summary: Additional research to explore gender- and sex-specific data on thyroid cancer would inform our understanding of the differences and similarities between men and women in susceptibility and detection of thyroid cancer and help to optimize disease management for all genders and both sexes.


  • Transfer of Stewardship of Thyroid

    by Anna M. Sawka

  • Open Access

    Decision-making in Surgery or Active Surveillance for Low Risk Papillary Thyroid Cancer During the COVID-19 Pandemic

    by Anna M. Sawka, Sangeet Ghai, Ogemdi Ihekire, Jennifer M. Jones, Amiram Gafni, Nancy N. Baxter, David P. Goldstein, on behalf of the Canadian Thyroid Cancer Active Surveillance Study Group

    We describe our experience conducting a prospective observational cohort study on the management of small, low risk papillary thyroid cancer during the COVID-19 pandemic. Our study participants are given the choice of active surveillance (AS) or surgery, and those in the AS arm are followed at the study center, whereas surgical patients undergo usual care. During the pandemic we have transitioned from in-person research patient visits to largely virtual care of patients under AS. As of 30 October 2020, we had enrolled 181 patients enrolled in our study (including 25 during the pandemic), of which 92.3% (167/181) consented to telephone communication and 79.0% (143/181) consented to secure videoconferencing communication. Prior to the pandemic, 74.5% (117/157) of our patients chose AS over surgery, whereas during the pandemic, 96.0% (24/25) chose AS. Of the 133 study patients who were under AS within the timeframe from 12 March 2020, to 30 October 2020, the percentage of patients who missed appointments was 8.3% (11/133, for neck ultrasound and physician visits, respectively) and delayed appointments was 23.3% (31/133). This preliminary data suggests that prospective observational research on AS of thyroid cancer can safely continue during the pandemic.


  • Papillary Thyroid Cancer with Central Neck Lymph Node Metastases

    by Alyse S. Goldberg, Lorne E. Rotstein, Anna M. Sawka